Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Sells China Rights for Diabetes Drug to Salubris

publication date: Oct 25, 2013
Fosun Pharma out-licensed China rights for a diabetes drug, a DPP4 inhibitor known as fotagliptin benzoate, to Shenzhen Salubris for 25 million RMB ($4.1 million). Earlier this week, Sellas Pharma of Greece bought global rights to the drug – with the exception of China – for $269 million (the deal included rights to cancer drug, a pan-HER inhibitor, which took the total value of the transaction up to $536 million). More details....

Stock Symbols: (SHA: 600196; HK: 02196) (SHE: 002294)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital